Neumora Therapeutics Inc [NMRA] stock prices are up 3.43% to $1.81 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NMRA shares have gain 2.26% over the last week, with a monthly amount drifted -16.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on December 01, 2025, when RBC Capital Mkts upgraded its rating to an Outperform but kept the price target unchanged to $7 for it. Previously, Guggenheim upgraded its rating to Buy on October 27, 2025, and kept the price target unchanged to $14. On September 16, 2025, downgrade downgraded it’s rating to Underweight. BofA Securities downgraded its rating to a Underperform but stick to its price target of $1 on April 02, 2025. William Blair downgraded its rating to a Mkt Perform. Stifel downgraded its rating to Hold for this stock on March 07, 2025, and downed its price target to $2. In a note dated March 07, 2025, Guggenheim downgraded a Neutral rating on this stock.
The stock price of Neumora Therapeutics Inc [NMRA] has been fluctuating between $0.61 and $11.57 over the past year. Currently, Wall Street analysts expect the stock to reach $7.5 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $1.81 at the most recent close of the market. An investor can expect a potential return of 314.36% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.33, Equity is -1.14 and Total Capital is -1.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7450 points at the first support level, and at 1.6800 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8700, and for the 2nd resistance point, it is at 1.9300.
Ratios To Look Out For
It’s worth pointing out that Neumora Therapeutics Inc [NASDAQ:NMRA]’s Current Ratio is 6.85. Also, the Quick Ratio is 6.85, while the Cash Ratio stands at 4.99.
Transactions by insiders
Recent insider trading involved Aurora Daljit Singh, that happened on Nov 11 ’25 when 0.11 million shares were sold. Director, Aurora Family Trust completed a deal on Nov 11 ’25 to buy 0.11 million shares. Meanwhile, Director Burow Kristina bought 1.92 million shares on Oct 27 ’25.
